ストックスクリーナーアプリを入手
1.02
2.86%
-0.03
アフターアワーズ：
1.00
-0.02
-1.96%
前日終値:
$1.05
開ける：
$1.06
24時間の取引高:
47,087
Relative Volume:
0.09
時価総額：
$8.24M
収益：
$2.35M
当期純損益:
$-2.56M
株価収益率:
-2.2763
EPS:
-0.4481
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-32.45%
1か月 パフォーマンス:
-36.65%
6か月 パフォーマンス:
-41.72%
1年 パフォーマンス:
-53.63%
1日の値動き範囲:
$1.01
$1.0794
1週間の範囲:
$1.00
$1.53
52週間の値動き範囲:
$1.00
$2.483
Immuron Limited Adr Stock (IMRN) Company Profile
IMRN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
1.02 | 8.49M | 2.35M | -2.56M | 0 | -0.4481 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immuron Limited Adr (IMRN) 最新ニュース
Orla Mining Ltd (ORLA) Performance and Fundamentals Dashboard tells a completely different story - setenews.com
Immuron stock tumbles after trial fails to meet primary endpoint By Investing.com - Investing.com UK
Immuron stock tumbles after trial fails to meet primary endpoint - Investing.com
Immuron Limited (IMRN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Immuron Limited announces quotation of new securities on ASX - MSN
Check Out IHS Holding Ltd (IHS)’s Trade Data Rather Than the Analysts’ Views - setenews.com
You might want to take a look at Embecta Corp (EMBC) now - setenews.com
Why UiPath Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
ANWA Forecast — Price Target — Prediction for 2026 - TradingView
Immuron Limited (IMRN) Plunges Amidst Management Uncertainty and Bearish Market Sentiment - Markets Financial Content
Immuron New U.S. Department of Defense Award & Clinical Trial Update - GlobeNewswire Inc.
Immuron New U.S. Department of Defense Award & Clinical Trial Update - Sahm
[6-K] Immuron Ltd Current Report (Foreign Issuer) | IMRN SEC FilingForm 6-K - Stock Titan
Why Immuron Limited (ANW) stock gets analyst attentionJuly 2025 Recap & Safe Capital Growth Stock Tips - newser.com
IMRN Stock Price and Chart — NASDAQ:IMRN - TradingView
How Immuron Limited Depositary Receipt stock benefits from global expansion2025 Macro Impact & AI Driven Price Forecasts - Fundação Cultural do Pará
Does Immuron Limited (Common Stock) (ANWA) stock trade below intrinsic valueJuly 2025 Price Swings & Risk Controlled Daily Plans - Fundação Cultural do Pará
Immuron Reports Strong FY2025 Results and Outlines FY2026 Plans - TipRanks
[6-K] Immuron Ltd Current Report (Foreign Issuer) - Stock Titan
Immuron Limited Announces Quotation of New Securities on ASX - TipRanks
Holdings of Immuron Limited ADR (IMRN) are aligned with the stars - Setenews
Immuron Limited Receives FDA Approval for IMM-529 Investigational New Drug Application for Clostridioides difficile Infection Treatment - Quiver Quantitative
Immuron IMM-529 IND approved by FDA - GlobeNewswire
Immuron CEO to Present at AusBiotech Invest 2025 Conference - MSN
Immuron Announces Clinical Trial Update - Sahm
Immuron Ltd (IMC:ASX) - smallcaps.com.au
IMRN furnishes 6-K with ASX updates and Exhibit 99.1 - Stock Titan
Immuron Ltd. (ADR) (US45254U1016.SG) Stock Price, News, Quote & History - Yahoo
Immuron Q1 FY26 YoY growth - Finviz
Immuron Limited Announces 2025 Annual General Meeting - MSN
Immuron Submits IMM-529 IND to FDA - markets.businessinsider.com
Immuron (IMRN) Seeks FDA Green Light for Novel C. diff Treatment - GuruFocus
Immuron Limited Submits IND Application to FDA for IMM-529 to Combat Clostridioides difficile Infection - Quiver Quantitative
$400M Market Potential: Immuron's C. Difficile Drug IMM-529 Heads to FDA as Company Advances 3 Key Programs - Stock Titan
Immuron Limited Secures Auditor Consent for Financial Filings - MSN
What analysts say about Immuron Limited ANW stockBear Market Strategies & Low Risk Capital Gains - earlytimes.in
Is Immuron Limited Depositary Receipt forming a reversal patternJuly 2025 Earnings & Low Risk Entry Point Guides - newser.com
Is it too late to sell Immuron Limited Depositary ReceiptMarket Activity Report & Fast Moving Trade Plans - Newser
Does Immuron Limited Depositary Receipt fit your quant trading modelJuly 2025 Price Swings & High Win Rate Trade Tips - Newser
Statistical indicators supporting Immuron Limited Depositary Receipt’s strengthPortfolio Risk Summary & Real-Time Sentiment Analysis - Newser
What institutional flow reveals about Immuron Limited Depositary ReceiptEarnings Growth Summary & Entry Point Strategy Guides - Newser
Immuron Limited Depositary Receipt stock trend forecastWeekly Investment Summary & AI Optimized Trading Strategy Guides - Newser
Visualizing Immuron Limited Depositary Receipt stock with heatmapsAI Trading Forecast Based on Big Data - Newser
BNY Mellon Increases Stake in Immuron Limited - TipRanks
Immuron Limited Announces Cessation of Securities - TipRanks
What drives Immuron Limited Depositary Receipt stock priceHigh-yield capital appreciation - jammulinksnews.com
Immuron - GlobeNewswire Inc.
immuron ltd files for quotation of securities on ASX - Investing.com
IMRNImmuron Ltd Latest Stock News & Market Updates - Stock Titan
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) - BioSpace
Immuron: Targeted oral antibodies to treat infectious diseases - Innovation News Network
Immuron Limited Adr (IMRN) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):